NO2018002I2 - Insulin degludec i alle dens former som de er beskyttet av basispatentet - Google Patents

Insulin degludec i alle dens former som de er beskyttet av basispatentet

Info

Publication number
NO2018002I2
NO2018002I2 NO2018002C NO2018002C NO2018002I2 NO 2018002 I2 NO2018002 I2 NO 2018002I2 NO 2018002 C NO2018002 C NO 2018002C NO 2018002 C NO2018002 C NO 2018002C NO 2018002 I2 NO2018002 I2 NO 2018002I2
Authority
NO
Norway
Prior art keywords
protected
forms
insulin degludec
basic patent
basic
Prior art date
Application number
NO2018002C
Other languages
English (en)
Other versions
NO2018002I1 (no
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO2018002I1 publication Critical patent/NO2018002I1/no
Publication of NO2018002I2 publication Critical patent/NO2018002I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO2018002C 2003-08-05 2018-01-11 Insulin degludec i alle dens former som de er beskyttet av basispatentet NO2018002I2 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301129 2003-08-05
US49545103P 2003-08-14 2003-08-14
PCT/DK2004/000511 WO2005012347A2 (en) 2003-08-05 2004-07-22 Novel insulin derivatives

Publications (2)

Publication Number Publication Date
NO2018002I1 NO2018002I1 (no) 2018-01-11
NO2018002I2 true NO2018002I2 (no) 2018-08-20

Family

ID=34117520

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20061026A NO340925B1 (no) 2003-08-05 2006-03-02 Nye insulinderivater
NO2018003C NO2018003I1 (no) 2003-08-05 2018-01-11 Combination of insulin degludec and insulin aspart
NO2018002C NO2018002I2 (no) 2003-08-05 2018-01-11 Insulin degludec i alle dens former som de er beskyttet av basispatentet

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO20061026A NO340925B1 (no) 2003-08-05 2006-03-02 Nye insulinderivater
NO2018003C NO2018003I1 (no) 2003-08-05 2018-01-11 Combination of insulin degludec and insulin aspart

Country Status (18)

Country Link
US (3) US7615532B2 (no)
EP (3) EP2107069B1 (no)
JP (1) JP4463814B2 (no)
KR (1) KR101159559B1 (no)
AU (2) AU2004261353B2 (no)
BE (2) BE2013C035I2 (no)
BR (1) BRPI0413276B8 (no)
CA (1) CA2531988C (no)
CY (3) CY1113850T1 (no)
FR (2) FR13C0035I2 (no)
HU (1) HUS1300033I1 (no)
IL (1) IL172980A (no)
LU (2) LU92213I2 (no)
MX (1) MXPA06001283A (no)
NO (3) NO340925B1 (no)
PL (1) PL2107069T3 (no)
RU (1) RU2518460C2 (no)
WO (1) WO2005012347A2 (no)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1648933T1 (sl) * 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Dolgo delujoäś inzulinski derivat in metoda zanj
EP2107069B1 (en) 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
US20080171695A1 (en) * 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
US8067362B2 (en) 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
ES2371361T3 (es) * 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
US8722620B2 (en) 2006-02-27 2014-05-13 Novo Nordisk A/S Insulin derivatives
WO2007104736A2 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
US8293965B2 (en) 2006-04-28 2012-10-23 Kimberly-Clark Worldwide, Inc. Antimicrobial site dressings
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
EP2386572B1 (en) * 2006-05-09 2015-07-08 Novo Nordisk A/S Insulin derivative
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
JP5097900B2 (ja) * 2006-06-27 2012-12-12 独立行政法人物質・材料研究機構 有機酸又はこれらの誘導体の活性エステル体の製造方法
CN101573133B (zh) * 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
JP5864834B2 (ja) 2006-09-22 2016-02-17 ノボ・ノルデイスク・エー／エス プロテアーゼ耐性のインスリンアナログ
EP2152245B1 (en) 2007-04-30 2015-12-02 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
AU2008257505B2 (en) * 2007-06-01 2013-05-16 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
JP5721432B2 (ja) * 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
RU2514430C2 (ru) * 2007-08-15 2014-04-27 Ново Нордиск А/С Аналоги инсулина с ацильной и алкиленгликолевой группировкой
CN101157725B (zh) * 2007-10-24 2012-07-25 中国药科大学 人胰岛素类似物的制备方法及用途
US8710000B2 (en) 2007-11-08 2014-04-29 Novo Nordisk A/S Insulin derivative
US8937042B2 (en) 2007-11-16 2015-01-20 Novo Nordisk A/S Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide
EP2254905B1 (en) 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910570B1 (en) 2008-03-18 2016-10-12 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
ES2561208T3 (es) 2008-09-12 2016-02-25 Novo Nordisk A/S Método de acilación de un péptido o una proteína
US9603904B2 (en) * 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
RU2525393C2 (ru) 2009-01-23 2014-08-10 Ново Нордиск А/С Производные fgf21 со связующим альбумина а-в-с-d-e- и их применение
US8835379B2 (en) 2009-10-30 2014-09-16 Novo Nordisk A/S Derivatives of CGRP
CN102753150A (zh) 2010-01-12 2012-10-24 诺沃—诺迪斯克有限公司 用于口服给予胰岛素肽的药物组合物
US9234192B2 (en) 2010-02-16 2016-01-12 Novo Nordisk A/S Conjugated proteins
EP2536434B1 (en) 2010-02-16 2016-04-20 Novo Nordisk A/S Purification method
KR20130092972A (ko) 2010-05-10 2013-08-21 노보 노르디스크 에이/에스 인슐린-아연 복합체의 제조 방법
WO2011146973A1 (en) 2010-05-25 2011-12-01 Monash University Insulin analogues
JP5931857B2 (ja) 2010-06-23 2016-06-08 ノヴォ ノルディスク アー／エス 追加のジスルフィド結合を含有するインスリン誘導体
EP2585483A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Human insulin containing additional disulfide bonds
CN102947331B (zh) 2010-06-23 2016-08-03 诺沃—诺迪斯克有限公司 包含额外的二硫键的胰岛素类似物
JP2013540771A (ja) 2010-10-15 2013-11-07 ノヴォ ノルディスク アー／エス 新規ｎ末端修飾インスリン誘導体
JP6049625B2 (ja) * 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
WO2012055967A2 (en) 2010-10-27 2012-05-03 Novo Nordisk A/S Treating diabetes melitus using insulin injections administered with varying injection intervals
EP2651432A1 (en) 2010-12-14 2013-10-23 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
JP2014510516A (ja) 2011-02-15 2014-05-01 ノヴォ ノルディスク アー／エス 長時間作用性ｉｌ−１受容体アンタゴニスト
MX2013011175A (es) * 2011-03-28 2013-11-01 Novo Nordisk As Analogos de glucagon novedosos.
JP6030630B2 (ja) 2011-04-14 2016-11-24 ノヴォ ノルディスク アー／エス 経口ペプチド送達のための脂肪酸アシル化アミノ酸
JP6058646B2 (ja) 2011-06-15 2017-01-11 ノヴォ ノルディスク アー／エス 多置換インスリン
JP6352806B2 (ja) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
CN103443122B (zh) * 2011-12-15 2016-05-11 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
EP2794648A1 (en) 2011-12-21 2014-10-29 Novo Nordisk A/S N-terminally modified insulin derivatives
ES2594303T3 (es) 2012-04-11 2016-12-19 Novo Nordisk A/S Formulaciones de insulina
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
JP6262206B2 (ja) 2012-05-01 2018-01-17 ノヴォ ノルディスク アー／エス 医薬組成物
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP6285447B2 (ja) 2012-10-17 2018-02-28 ノヴォ ノルディスク アー／エス 経口ペプチド送達用の脂肪酸アシル化ｄ−アミノ酸
EP2934569A1 (en) 2012-12-21 2015-10-28 Sanofi Exendin-4 derivatives
EP2976096B1 (en) * 2013-03-20 2019-02-27 Novo Nordisk A/S Insulin dosing regimen
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
MX366636B (es) 2013-10-07 2019-07-17 Novo Nordisk As Nuevo derivado de un análogo de insulina.
FR3013049B1 (fr) 2013-11-14 2015-11-13 You-Ping Chan Analogue de l'insuline glargine
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
CN106029088A (zh) 2014-02-18 2016-10-12 诺和诺德股份有限公司 稳定的胰高血糖素类似物以及用于治疗低血糖的用途
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
JP2018531901A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
CN114478747B (zh) * 2016-08-02 2024-06-14 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
US11673933B2 (en) 2016-11-28 2023-06-13 Novo Nordisk A/S Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
US11278596B2 (en) 2016-11-28 2022-03-22 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
US20180169190A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
KR20200119237A (ko) 2018-02-09 2020-10-19 지앙수 헨그루이 메디슨 컴퍼니 리미티드 인간 인슐린 유사체의 코돈 최적화된 전구체 유전자 및 신호 펩티드 유전자
WO2019223752A1 (zh) 2018-05-24 2019-11-28 江苏恒瑞医药股份有限公司 一种重组人胰岛素或其类似物的前体的制备方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
EP3815106A1 (en) 2018-06-26 2021-05-05 Novo Nordisk A/S System providing dose recommendations for basal insulin titration
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
JP2022542301A (ja) 2019-07-31 2022-09-30 イーライ リリー アンド カンパニー リラキシン類似体およびその使用方法
US20230126068A1 (en) 2019-12-30 2023-04-27 Gan & Lee Pharmaceuticals Co., Ltd. Insulin Derivative
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5382574A (en) 1989-12-21 1995-01-17 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide
DK45590D0 (no) 1990-02-21 1990-02-21 Novo Nordisk As
JP3193398B2 (ja) 1991-07-23 2001-07-30 サンデン株式会社 ショ−ケ−ス
ATE227583T1 (de) 1991-12-20 2002-11-15 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
NZ273285A (en) * 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
WO1996010417A1 (en) 1994-10-04 1996-04-11 Novo Nordisk A/S PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
ATE245659T1 (de) 1995-03-17 2003-08-15 Novo Nordisk As Insulinabkömmlinge
EP1516628B1 (en) 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5898267A (en) * 1996-04-10 1999-04-27 Mcdermott; Kevin Parabolic axial lighting device
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AU3255297A (en) * 1996-07-11 1998-02-09 Novo Nordisk A/S Selective acylation method
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ATE264871T1 (de) 1996-07-26 2004-05-15 Aventis Pharma Gmbh Insulinderivate mit erhöhter zinkbindung
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
DE69806362T2 (de) 1997-03-20 2003-01-30 Novo Nordisk As Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
EP1627642A3 (en) * 1997-03-20 2006-04-19 Novo Nordisk A/S Zinc free insulin crystals for use in pulmonary compositions
AU6611898A (en) 1997-03-20 1998-10-20 Novo Nordisk A/S Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
DK1283051T3 (da) 1997-06-13 2006-10-16 Lilly Co Eli Stabile insulinformuleringer
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
ATE243711T1 (de) * 1997-10-24 2003-07-15 Novo Nordisk As Aggregate von menschlichen insulinderivaten
US20020155994A1 (en) 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
CA2306905A1 (en) 1997-10-24 1999-05-06 Eli Lilly And Company Fatty acid-acylated insulin analogs
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
ATE290877T1 (de) 1998-01-09 2005-04-15 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
IL142011A0 (en) 1998-10-16 2002-03-10 Novo Nordisk As Stable concentrated insulin preparations for pulmonary delivery
CN100553678C (zh) 1999-02-22 2009-10-28 巴克斯特国际有限公司 新的无白蛋白的因子ⅷ制剂
AU4450700A (en) 1999-04-27 2000-11-10 Eli Lilly And Company Insulin crystals for pulmonary administration
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
IL161848A0 (en) 2001-12-20 2005-11-20 Lilly Co Eli Insulin moldecule having protracted time action
US8003605B2 (en) 2002-03-13 2011-08-23 Novo Nordisk A/S Minimising body weight gain in insulin treatment
AU2003236201A1 (en) 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
PL376219A1 (en) 2002-10-29 2005-12-27 Alza Corporation Stabilized, solid-state polypeptide particles
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
JPWO2004069259A1 (ja) 2003-02-07 2006-05-25 味の素株式会社 糖尿病治療剤
PT1597367E (pt) 2003-02-19 2010-09-02 Scripps Research Inst Antigénio glicoproteína sima 135 expresso em células tumorais humanas metastáticas
DE602004029630D1 (de) 2003-03-04 2010-12-02 Technology Dev Co Ltd Injizierbare Insulinzubereitung mit Langzeitwirkung und Verfahren zur dessen Herstellung und Verwendung
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
EP2107069B1 (en) * 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
CN101955527B (zh) 2003-08-05 2016-04-20 诺沃挪第克公司 新型胰岛素衍生物
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
WO2005021022A2 (en) 2003-09-01 2005-03-10 Novo Nordisk A/S Stable formulations of peptides
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
CA2551510C (en) 2003-12-23 2013-07-30 Pharmacia Corporation Stable growth hormone liquid formulation
ES2328048T3 (es) 2004-03-12 2009-11-06 Biodel, Inc. Composiciones de insulina con absorcion mejorada.
ES2381674T3 (es) 2004-06-01 2012-05-30 Ares Trading S.A. Método de estabilizar proteínas
CA2576549C (en) 2004-08-12 2011-01-18 Schering Corporation Stable pegylated interferon formulation
SI1778723T1 (sl) 2004-08-17 2013-02-28 Regeneron Pharmaceuticals, Inc. Formulacije IL-1 antagonista
US20090011976A1 (en) 2004-11-12 2009-01-08 Novo Nordisk A/S Stable Formulations Of Peptides
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
CA2593112A1 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
US8067362B2 (en) * 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
US8722620B2 (en) 2006-02-27 2014-05-13 Novo Nordisk A/S Insulin derivatives
WO2007121256A2 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
EP2386572B1 (en) 2006-05-09 2015-07-08 Novo Nordisk A/S Insulin derivative
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
US8937042B2 (en) 2007-11-16 2015-01-20 Novo Nordisk A/S Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物

Also Published As

Publication number Publication date
EP1660531A2 (en) 2006-05-31
NO340925B1 (no) 2017-07-17
BE2013C038I2 (no) 2023-12-14
NO2018003I1 (no) 2018-01-11
CY1113850T1 (el) 2015-11-04
AU2010200497B2 (en) 2014-10-23
PL2107069T3 (pl) 2013-06-28
RU2518460C2 (ru) 2014-06-10
FR13C0035I2 (fr) 2014-03-07
AU2010200497A1 (en) 2010-03-04
AU2004261353A1 (en) 2005-02-10
CY2013027I2 (el) 2015-11-04
JP4463814B2 (ja) 2010-05-19
BE2013C035I2 (no) 2023-12-14
US20140349925A1 (en) 2014-11-27
LU92226I9 (no) 2018-11-19
CA2531988C (en) 2016-06-28
EP2264065A3 (en) 2011-07-27
BRPI0413276B8 (pt) 2021-05-25
EP2107069A2 (en) 2009-10-07
KR101159559B1 (ko) 2012-06-26
LU92213I2 (fr) 2013-08-23
US20060183668A1 (en) 2006-08-17
US20100009899A1 (en) 2010-01-14
LU92226I2 (fr) 2015-04-29
US7615532B2 (en) 2009-11-10
CA2531988A1 (en) 2005-02-10
RU2008152033A (ru) 2010-07-10
CY2013029I1 (el) 2015-11-04
FR13C0035I1 (no) 2013-08-09
LU92213I9 (no) 2018-11-19
EP2264065B1 (en) 2017-03-08
BRPI0413276B1 (pt) 2020-03-03
IL172980A (en) 2013-10-31
WO2005012347A2 (en) 2005-02-10
CY2013029I2 (el) 2015-11-04
NO20061026L (no) 2006-03-02
KR20060132543A (ko) 2006-12-21
HUS1300033I1 (hu) 2016-08-29
AU2004261353B2 (en) 2009-12-10
MXPA06001283A (es) 2006-04-11
CY2013027I1 (el) 2015-11-04
NO2018002I1 (no) 2018-01-11
JP2007523881A (ja) 2007-08-23
IL172980A0 (en) 2006-06-11
EP2107069A3 (en) 2009-11-25
EP2264065A2 (en) 2010-12-22
US8828923B2 (en) 2014-09-09
EP2107069B1 (en) 2013-01-16
FR13C0038I1 (fr) 2013-08-09
BRPI0413276A (pt) 2006-10-10
WO2005012347A3 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
NO2018002I2 (no) Insulin degludec i alle dens former som de er beskyttet av basispatentet
NO2014004I1 (no) Alogliptin i alle former beskyttet av patentet
NO2013015I1 (no) Elvitegravir i alle former beskyttet ved basispatentet
DK1902037T3 (da) 2,4-diamino-pyrimidiner som auroainhibitorer
MXPA05009112A (es) Mezclas herbicidas de accion sinergica.
DE502004007168D1 (de) Synergistische insektizide mischungen
DE502005004191D1 (de) Reinigungsschacht.
PL1888031T3 (pl) Preparaty analogu glp-1
DK1856042T3 (da) Substituerede gamma-lactamer som terapeutiske midler
DE502004009334D1 (de) Synergistische insektizide mischungen
DK1473997T3 (da) Synergistiske insekticide blandinger
DE502005002055D1 (de) Synergistische insektizide mischungen
ATE455555T1 (de) Glp-1-analoga
DE60325370D1 (de) Synergistische herbizide zusammensetzungen
DE60316453D1 (de) Synergistiche herbizide zusammensetzungen
EP1852431A4 (en) OPTICALLY ACTIVE TETRAHYDRONAPHTALENE DERIVATIVE
EP1723145A4 (en) SUBSTITUTED 5,12-DIAZENZOANTHRACENANALOGA
ATE504290T1 (de) Zusammensetzungen mit neramexan
NO20051756L (no) Stol
GB0500071D0 (en) Cleaning formulation
FI6942U1 (fi) Tuoli
NO20040180L (no) Stol
SE0402778L (sv) Stol
ES1052462Y (es) Sofa de facil desmontaje por elementos.
FI20050938A0 (fi) Istuin